Assessment of non-classical lymphocyte populations in patients with advanced lung cancer treated with Biomodulina T following platinum-based chemotherapy

Abstract

Aim: Currently, malignant diseases represent a health issue worldwide. Among these, lung cancer is of growing importance, due to its high incidence and mortality. Chemotherapy, one of the most frequently used treatments, has shown its ability to induce accelerated immunosenescence in classic and as well non-classic lymphocyte compartments, being less described in the latter. The immune restoration strategies have demonstrated their ability to reverse immunosenescence and exhaustion markers in conventional lymphocyte subpopulations after chemotherapy. However, the possible immunorestorative effect on non-classical lymphocytes has not been widely reported. The aim of this study was to evaluate the effect of chemotherapy and the administration of a thymic polypeptide factor on non-classical lymphocyte populations in patients with advanced lung cancer.

Methods: Eighteen patients with advanced lung cancer, were evaluated at baseline before and after platinum-based chemotherapy (4–6 cycles). All patients could complete treatment with a thymic polypeptide factor [Biomodulina T (BT)] at the end of chemotherapy. Blood from patients was collected by venipuncture in heparinized tubes before and after chemotherapy and at the end of BT treatment to analyze the frequencies of non-classical immune subpopulations by flow cytometry.

Results: Natural killer (NK), natural killer T cells (NKT), and double-positive T lymphocyte (DPT) proportions reached normal values in patients diagnosed with advanced lung cancer before receiving cytotoxic treatment. Chemotherapy did not induce modifications in the total percent of NK, NKT, and DPT populations in these patients. However, the administration of BT decreased DPTs and NK cells expressing the cluster of differentiation (CD)57 molecule, which is considered a marker of immunosenescence.

Conclusions: These results suggest a lower influence of platinum-based chemotherapy on non-classical lymphocytes and the potential to generate a reconstitution of lymphocyte subpopulations in patients with advanced lung cancer by using the thymic factor BT, which reveals a new possibility for improving the response to cancer immunotherapies [Cuban Public Registry of Clinical Trial (RPCEC, https://rpcec.sld.cu/en/trials/RPCEC00000358-En) identifier: RPCEC00000358].

Keywords

Natural killer / natural killer T cells / double-positive T lymphocytes / non-small cell lung cancer / CD57 / Biomodulina T / chemotherapy

References

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71: 209-49.

[2] Dama E, Melocchi V, Dezi F, Pirroni S, Carletti RM, Brambilla D, et al. An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers. Clin Cancer Res. 2017; 23: 62-72.

[3] Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015; 16: e165-72.

[4] Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019; 69: 363-85.

[5] Aunan JR, Cho WC, Søreide K. The Biology of Aging and Cancer: A Brief Overview of Shared and Divergent Molecular Hallmarks. Aging Dis. 2017; 8: 628-42.

[6] Fulop T, Larbi A, Kotb R, Pawelec G. Immunology of aging and cancer development. Interdiscip Top Gerontol. 2013; 38: 38-48.

[7] Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022; 12: 31-46.

[8] Franceschi C, Bonafè M, Valensin S, Olivieri F, Luca MD, Ottaviani E, et al. Inflamm-aging: An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000; 908: 244-54.

[9] Fulop T, Larbi A, Dupuis G, Page AL, Frost EH, Cohen AA, et al. Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes? Front Immunol. 2018; 8: 1960.

[10] Kared H, Martelli S, Ng TP, Pender SLF, Larbi A. CD57 in human natural killer cells and T-lymphocytes. Cancer Immunol Immunother. 2016; 65: 441-52.

[11] Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, Crotty LE, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8⁺ T cells . Blood. 2003; 101: 2711-20.

[12] Nielsen CM, White MJ, Goodier MR, Riley EM. Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease. Front Immunol. 2013; 4: 422.

[13] Strioga M, Pasukoniene V, Characiejus D. CD8⁺CD28⁻ and CD8⁺CD57⁺ T cells and their role in health and disease . Immunology. 2011; 134: 17-32.

[14] Suárez GM, Añé-Kourí AL, González A, Lorenzo-Luaces P, Neninger E, Salomón EE, et al. Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer. Cancer Immunol Immunother. 2021; 70: 1735-43.

[15] Suárez GM, Catalá M, Peña Y, Portela S, Añé-Kourí AL, González A, et al. Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy. Front Oncol. 2022; 12: 823287.

[16] Saavedra D, Fuertes SA, Suárez GM, González A, Lorenzo-Luaces P, García B, et al. Biomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly. Exp Gerontol. 2019; 124: 110633.

[17] Villegas-Valverde CA, Kokuina E, Breff-Fonseca MC. Estimating Normal Values of Rare T-Lymphocyte Populations in Peripheral Blood of Healthy Cuban Adults. MEDICC Rev. 2018; 20: 20-6.

[18] Kokuina E, Breff-Fonseca MC, Villegas-Valverde CA, Mora-Díaz I. Normal Values of T, B and NK Lymphocyte Subpopulations in Peripheral Blood of Healthy Cuban Adults. MEDICC Rev. 2019; 21: 16-21.

[19] Javeed A, Ashraf M, Riaz A, Ghafoor A, Afzal S, Mukhtar MM. Paclitaxel and immune system. Eur J Pharm Sci. 2009; 38: 283-90.

[20] Verma R, Foster RE, Horgan K, Mounsey K, Nixon H, Smalle N, et al. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res. 2016; 18: 10.

[21] Aldarouish M, Su X, Qiao J, Gao C, Chen Y, Dai A, et al. Immunomodulatory effects of chemotherapy on blood lymphocytes and survival of patients with advanced non-small cell lung cancer. Int J Immunopathol Pharmacol. 2019; 33.

[22] Lopez-Vergès S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56^dimCD16⁺ NK-cell subset . Blood. 2010; 116: 3865-74.

[23] Sun JC, Lopez-Verges S, Kim CC, DeRisi JL, Lanier LL. NK cells and immune “memory”. J Immunol. 2011; 186: 1891-7.

[24] Forconi CS, Oduor CI, Oluoch PO, Ong’echa JM, Münz C, Bailey JA, et al. A New Hope for CD56^negCD16^pos NK Cells as Unconventional Cytotoxic Mediators: An Adaptation to Chronic Diseases . Front Cell Infect Microbiol. 2020; 10: 162.

[25] Marini A, Avino D, Donno MD, Romano F, Morganti R. Percentages and Absolute Numbers of CD4+ CD8+ Double-positive T Lymphocytes in the Peripheral Blood of Normal Italian Subjects: Relationship with Age and Sex. Turk J Haematol. 2020; 37: 125-6.

[26] Bohner P, Chevalier MF, Cesson V, Rodrigues-Dias S, Dartiguenave F, Burruni R, et al. Double Positive CD4⁺CD8⁺ T Cells Are Enriched in Urological Cancers and Favor T Helper-2 Polarization . Front Immunol. 2019; 10: 622.

[27] King R, Tuthill C. Chapter Seven - Immune Modulation with Thymosin Alpha 1 Treatment. Vitam Horm. 2016; 102: 151-78.

[28] Sugahara S, Ichida T, Yamagiwa S, Ishikawa T, Uehara K, Yoshida Y, et al. Thymosin-α1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B. Hepatol Res. 2002; 24: 346-54.

[29] Ramos EH, Suárez VM, Hernández IC, Gomez RP, Rivera DG, Zamora MCR, et al. Effect of Biomodulina-T® and VA-MENGOC-BC® on lymphocyte subpopulations in older adults. Exp Gerontol. 2021; 153: 111497.